Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-29T05:19:26.883Z Has data issue: false hasContentIssue false

Monoaminoxidase inhibitors as a cause of serotonin syndrome – a systematic case review based on meta-analytic principles

Published online by Cambridge University Press:  13 August 2021

P. Truedson*
Affiliation:
Sunderby Research Unit, Umeå University, Deparment of clinical science, division of psychiatry, Luleå, Sweden
M. Ott
Affiliation:
Department Of Public Health And Clinical Medicine – Medicine, Umeå University, Umeå, Sweden
H. Wikström
Affiliation:
Sunderby Research Unit, Umeå University, Deparment of clinical science, division of psychiatry, Luleå, Sweden
M. Maripuu
Affiliation:
Department Of Clinical Sciences- Psychiatry, Umeå University, Umeå, Sweden
K. Lindmark
Affiliation:
Department Of Public Health And Clinical Medicine- Medicine, Umeå University, Umeå, Sweden
U. Werneke
Affiliation:
Sunderby Research Unit, Umeå University, Deparment of clinical science, division of psychiatry, Luleå, Sweden
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Serotonin syndrome (SS) is a toxic state characterized by increased serotonin activity. It has been suggested that severe serotonin syndrome usually involves monoaminoxidase inhibitors (MAOIs).

Objectives

To quantify in how far severe SS is associated with MAOIs.

Methods

Systematic review and quantitative analysis of all SS cases published between 1 January 2004 and 31 December 2014. Severe SS was defined as cases, either requiring intensive care or resulting in death. Cases were included if they met the diagnostic criteria for SS according to at least one of the three diagnostic criteria systems (Hunter, Radomski and Sternbach).

Results

Of the 299 included cases, 118 (39%) met the definition for severe SS. Eight cases had insufficient information to enable severity classification. Of the severe cases, 48 (40%) involved a MAOI. Of these, 67% related to psychiatric MAOIs, such as phenelzine and moclobemide and 33% to a somatic MAOI, such as methylene blue and linezolid. Of the remaining 173 non-severe SS cases, 24 cases (13%) involved a MAOI. In these, 12% related to a psychiatric MAOI and 83% to a somatic MAOI. One case (4%) had a combination of both. The odds ratio for MAOI involvement in severe versus non-severe serotonin syndrome was 4.3 (CI 2.4 – 7.5; p < 0.001).

Conclusions

In the majority of published case reports, drugs other than MAOIs are involved in serotonin syndrome, even in severe cases. MAOIs are, however, more common in severe serotonin syndrome than in non-severe cases.

Conflict of interest

M. Ott: scientific advisory board member of Astra Zeneca, Sweden. U. Werneke: received funding for educational activities on behalf of Norrbotten Region; Astra Zeneca, Eli Lilly, Janssen, Novartis, Otsuka/Lundbeck, Servier, Shire, Sunovion. Others: None

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.